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BACKGROUND In the mid 1990s, two unstable angina risk prediction models were proposed but neither has
been validated on separate population or compared.
OBJECTIVES The purpose of this study was to compare patient outcome among high, medium and low risk
unstable angina patients defined by the Agency for Health Care Policy and Research
(AHCPR) guideline to similar risk groups defined by a validated model from our institution
(RUSH).
METHODS Four hundred sixteen patients consecutively admitted to the hospital with unstable angina
between January 1, 1995, and December 31, 1997, were prospectively evaluated for risk
factors. The presence of major adverse events such as myocardial infarction (MI), death and
heart failure was assessed for each patient by chart review.
RESULTS The composite end point of heart failure, MI or death occurred in 3% and 5% of the RUSH
and AHCPR low risk categories, respectively, and in 8% and 10% of AHCPR and
RUSH high risk categories, respectively. Recurrent ischemic events were best predicted
by the RUSH model (high: 24% vs medium: 12% and low: 10%, p 5 0.029), but not by
the AHCPR model (high: 14% vs medium: 13% and low: 9%, p 5 0.876). The RUSH
model identified five times more low risk patients than the AHCPR model.
CONCLUSIONS Both models identify patients with low and high event rates of MI, death or heart failure.
However, the RUSH model allowed for five times more patients to be candidates for
outpatient evaluation (low risk) with a similar observed event rate to the AHCPR model; also,
the RUSH model more successfully predicted ischemic complications. We conclude that the
RUSH model can be used clinically to identify patients for early noninvasive evaluation,
thereby improving cost effectiveness of care. (J Am Coll Cardiol 2000;36:1803–8) © 2000 by
the American College of Cardiology
In 1994, the Agency for Health Care Policy and Research
(AHCPR) published evaluation and management guide-
lines for unstable angina (1). The management algorithms
were driven by the assessment of acuity into low, medium
and high risk categories. This risk prediction model based
on pain syndrome, ECG changes, age and degree of clinical
evidence of heart failure has not been validated to date (and
to our knowledge).
Assessing risk of subsequent event in patients who
present with chest pain has been an established focus of the
investigation over the last 20 years (2–13). Earlier studies
focused on the accuracy of predicting an acute myocardial
infarction (MI) with the goal of reducing inappropriate
admissions to the Coronary Care Unit while at the same
time achieving a high sensitivity for diagnosing MI (2,3,14–
18). Braunwald (19) called attention to the need of having
a risk stratification scheme in unstable angina with the
purposes of better matching of resources to need, better
designing of clinical research trial designs and improving
quality assurance methods. His model has been studied
subsequently by others (20) who have demonstrated its
correlation with lesion morphology and outcome in unstable
angina. Our group (8) also has validated a number of the
Braunwald predictors along with age and the presence of
diabetes as a way to assess risk of major cardiac complica-
tions in unstable angina.
The purpose of this study was to prospectively compare
both the AHCPR risk model with the model developed by
our group (RUSH model) from the standpoint of clinical
outcome and resource utilization.
METHODS
Patients. All patients with unstable angina (total group,
n 5 416) admitted to the Coronary Care or Coronary
Stepdown Units at Rush-Presbyterian-St. Luke’s Medical
Center between January 1, 1996, and December 31, 1997,
were prospectively evaluated in this study. Patients were
identified daily by a nurse coordinator by both admission
logs and chart review. Patients were diagnosed as having
unstable angina pectoris if they had either of the following:
1) Ischemic type of chest pain, either responsive to nitrates
or associated with ST depression, or T-wave inversion
.2mm occurring at rest and lasting $20 min; or
2) Progressive angina characterized by exertional ischemia
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pain increasing in frequency, duration, or at decreasing
levels of exertion.
Anginal equivalents such as shortness of breath were
excluded. An admission diagnosis of unstable angina was
excluded if the total creatine kinase (CK) level was greater
than twice the upper limit of normal for our laboratory
within the first 12 h of presentation to the Emergency
Department. These patients were classified as non Q MI.
All patients were treated by their attending physicians.
Guideline reminders summarizing the AHCPR recommen-
dation for evaluation and treatment of unstable angina were
posted on each patients’ chart.
Data analysis. The estimated risk of sustaining a major
cardiac complication using the RUSH model (8) was based
on the results of a previously validated multiple logistic
regression model. The model is calculated as the sum of
terms on the log odds scale as follows:
Log odds 5 23.551 1 1.743 z POSTMI 1 0.847 z IVNTG
1 1.342 z NO_BETA 1 1.034 z STDEPR
1 0.784 DIAB 1 0.039 z (AGE 65)
Where POSTMI indicates admission followed an MI
within 14 days, IVNTG indicates IV nitroglycerin was
required on admission, NO_BETA indicates the person
was receiving neither a beta-blocker nor on a rate-lowering
calcium channel blocker at admission, STDEPR indicates
that the person had ST segment depression on admission
ECG, DIAB indicates a history of diabetes and AGE is the
age in years. The probability (p) of a major event was
calculated as p 5 1/(1 1 e2log odds).
The entire population was then categorized into groups
of estimated probability of risk of major complications as
follows: estimated probability of major cardiac complication
,5%, low risk; 5.1% to 25%, medium risk; .25%, high risk.
These three strata were chosen to provide large enough
groups for adequate statistical comparison and to allow a
direct comparison with the AHCPR model, which is also
categorized as low, medium and high risk. Also, the
intervals were believed clinically appropriate and approxi-
mate the probabilities of risk achieved in other studies
(2,3,17).
The AHCPR risk prediction model was applied to all
patients (Table 1). Patients were identified as medium risk
if at least one medium risk factor was present and high risk
if at least one high risk factor was present.
Definition of outcome events. Major cardiac complica-
tions were defined by the occurrence of any of the following:
1) MI after the first 24 h defined by a CK .twice the upper
limit of normal and peaking after the first 24 h or the
development of new Q waves and CKMB index .10%;
2) congestive heart failure defined by documentation of a
new S3 or crackles after first 24 h or chest radiographic
evidence of pulmonary edema; and
3) death.
This composite of outcomes differed slightly from our
original report by excluding ventricular tachycardia .30 s
requiring drug therapy or ventricular fibrillation, which we
found to be uncommon.
Secondary end points of recurrent angina (steady chest
pain lasting at least 5 min and for which a charge in patient
therapy occurred including but not limited to administra-
tion of one sublingual nitroglycerin) and recurrent angina
with ST depression $ 1 mm beyond baseline ECG were
also tabulated. Interventional procedures were not treated as
Abbreviations and Acronyms
AHCPR 5 Agency for Health Care Policy and
Research
CK 5 creatinine kinase
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal angioplasty
Table 1. Agency for Health Care Policy and Research Risk Prediction Model of Death or Nonfatal Myocardial Infarction in Patients
With Symptoms Suggesting Unstable Angina*
High Risk Intermediate Risk Low Risk
At Least One of the Following Features
Must Be Present:
No High Risk Feature but Must Have
Any of the Following:
No High or Intermediate Risk Feature
but May Have Any of the Following:
Prolonged ongoing (.20 min) rest pain Rest angina now resolved, but not low likelihood
of CAD
Increased angina frequency, severity or duration
Pulmonary edema Rest angina (.20 min or relieved with rest or
nitroglycerin)
Angina provoked at a lower threshold
Angina with new or worsening MR murmur Angina with dynamic T-wave changes New onset angina within 2 wk to 2 mo
Rest angina with dynamic ST changes
$1 mm
Nocturnal angina Normal or unchanged ECG
Angina with S3 or rales New onset CCSC III or IV angina in the past
2 wk with moderate or high likelihood of
CAD
Angina with hypotension Q waves or ST depression $1 mm in multiple
leads; Age .65 yr
*CAD 5 coronary artery disease; MR 5 mitral regurgitation.
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end points of clinical outcome in either this study or in our
original description.
Data collection. Two nurse coordinators prospectively col-
lected all clinical predictors and demographic information
from the patient’s chart within 24 h of hospital admission.
Treatments and major in-hospital outcomes were obtained
by both reviewing the patient’s chart and interviewing the
patient’s physician on a daily basis. The data were subse-
quently entered in a relational database (Paradox; Ansa
Software; Scott’s Valley, California). Neither of these coor-
dinators was involved with the initial model development
and was not trained on it. Assignments of outcomes were
verified in two ways: 1) chart audits (J.E.C.) in a 10%
random sample and 2) checking discharge ICD-9 codes
obtained from the hospital information system.
Statistical analysis. Univariate comparisons were made
using chi-square tests for categorical variables. Analysis of
variance was used for normally distributed continuous vari-
able data.
RESULTS
Figure 1 demonstrates the frequency of patients in low,
medium and high risk groups for both models. The RUSH
model identified five times more low risk patients than the
AHCPR model while the AHCPR model identified more
high risk patients. Most patients were classified as interme-
diate risk using either model.
The baseline characteristics of each of the AHCPR risk
groups (low, medium or high [Table 2]) revealed that low
risk patients were younger, had no evidence of ST depres-
sion and were less likely to have had previous coronary
bypass surgery. The high risk patients more frequently had
more coronary angioplasty.
The baseline characteristics of each of the RUSH risk
groups (Table 2) revealed that high risk patients were the
eldest, and more frequently required IV nitroglycerin to
control ongoing chest pain. They also had more ST depres-
sion and were more likely to have diabetes or to have had a
recent MI than the other two groups. Low risk patients
were more likely to have hypercholesterolemia than the
other two groups and more frequently had prior treatment
with beta-blockers.
Treatments in hospital. The treatments received in hos-
pital are summarized in Table 3. In general, neither model
predicted medical or revascularization therapy, suggesting
that interventional revascularization procedures are not
guided by risk assessment. The medical therapies were also
not influenced by either model with the exception of IV
nitroglycerin in the RUSH categorization, which is con-
founded by being one of the variables used in the probability
estimate. There was a trend for more low risk AHCPR
Figure 1. Percentage of patients in low, medium and high risk groups for
each model. Open bar 5 RUSH; solid bar 5 AHCPR.
Table 2. Baseline Characteristics












(n 5 59) p Value
Age, yr (SD)*† 56 (9) 66 (13) 63 (17) 0.006 55 (15) 66 (12) 74 (11) 0.001
Prior beta-blocker use, n (%)† 9 (41) 148 (53) 70 (62) 0.103 93 (89) 126 (50) 8 (14) 0.001
Pain requiring IV Ntg, n (%)† 8 (36) 113 (40) 58 (51) 0.106 16 (15) 119 (47) 43 (73) 0.001
ST depression, n (%)*† 0 (0) 35 (13) 21 (19) 0.045 0 (9) 32 (13) 15 (25) 0.009
MI , 14 days, n (%)† 1 (5) 8 (3) 2 (2) 0.708 0 (0) 5 (2.0) 6 (10) 0.001
Diabetes, n (%)† 8 (36) 105 (37) 43 (38) 0.986 17 (16) 97 (39) 41 (70) 0.001
Male, n (%) 14 (64) 172 (62) 73 (65) 0.898 75 (71) 142 (57) 41 (70) 0.054
Hypertension, n (%) 17 (77) 195 (69) 70 (62) 0.223 77 (73) 162 (165) 42 (71) 0.223
Hypercholesterolemia, n (%) 13 (59) 116 (41) 52 (46) 0.220 57 (54) 167 (43) 16 (27) 0.003
Family history, n (%) 10 (46) 109 (39) 57 (50) 0.101 49 (47) 103 (41) 24 (41) 0.593
Tobacco history, n (%) 10 (46) 120 (43) 58 (51) 0.298 51 (49) 111 (44) 25 (42) 0.682
Previous MI, n (%) 4 (18) 85 (30) 37 (33) 0.397 38 (36) 76 (30) 12 (20) 0.106
Previous CABG, n (%) 4 (18) 80 (29) 45 (40) 0.036 26 (25) 82 (33) 21 (36) 0.245
Previous PTCA, n (%) 8 (36) 67 (24) 47 (42) 0.002 37 (35) 68 (27) 17 (29) 0.304
Crackles, n (%) 0 (0) 3 (1) 2 (2) 0.734 0 (0) 5 (2) 0 (0) 0.191
S3, n (%)* 0 (0) 7 (3) 5 (4) 0.414 1 (1) 8 (3) 3 (5) 0.287
Systolic murmur, n (%)*f 3 (14) 70 (25) 27 (24) 0.391 21 (20) 64 (26) 15 (25) 0.177
*Predictors used by Agency for Health Care Policy and Research (AHCPR); †predictors used by RUSH.f 5 by exam only, mitral regurgitation not confirmed; Ntg 5 nitroglycerin; SD 5 standard deviation; MI 5 myocardial infarction; CABG 5 coronary artery bypass graft;
PTCA 5 percutaneous transluminal coronary angioplasty.
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patients than high risk patients to receive percutaneous
transluminal coronary angioplasty (PTCA) but this was not
significant.
Outcomes in hospital. The hospital length of stay for each
risk group of both models is summarized in Table 4. The
overall length of stay was 5.7 6 4.0 days and the median was
5 days. The low risk groups’ length of stay was only one day
shorter than medium or high risk groups of both models
(not significant). The incidence of the composite end point
of heart failure, MI or death is shown in Table 5. The
RUSH model demonstrates a progressive but not statisti-
cally significant increase in the composite end point while
the AHCPR model shows little gradation in the composite
end point. The RUSH model does show a progressive
increase in risk of any complication (including recurrent
angina) whereas the AHCPR model does not (Table 5).
Furthermore, the RUSH model significantly predicts isch-
emic end points of recurrent angina (low, 10%; medium,
12%; and high, 24% [p 5 0.029] vs. AHCPR low, 9%;
medium, 13%; and high, 14% [p 5 0.876]) and recurrent
angina with ST depression than the AHCPR model (low,
1%; medium, 2%; and high, 9% [p 5 0.004] vs. AHCPR
low, 0%; medium, 3%; and high, 3% [p 5 1.00]) (Table 5).
The RUSH model also discriminated the end point of MI,
deaths, heart failure or recurrent angina among low, me-
dium and high risk groups compared to the AHCPR model
(Table 5). To further explore the accuracy of the RUSH
model, four risk strata were arbitrarily established for the
RUSH model (0 to ,5%, n 5 105; 5 to ,15%, n 5 171;
15 to ,25%, n 5 80; and $25%, n 5 59). The rates of a
major complication (MI or death or heart failure were 3%,
9%, 6% and 11%, respectively. Thus, the RUSH model
predicts very well in the lowest risk groups but overestimates
risk in the higher risk groups.
DISCUSSION
Conclusions. There are several important conclusions of
this study. First, risk stratification models do have value in
the early evaluation of unstable angina, especially in the low
risk category. Both models predicted patients who subse-
quently experienced less than a 5% incidence of cardiac
complications. Second, the RUSH model identified five
times more low risk patients than the AHCPR model. This
allows more patients to be evaluated by noninvasive testing
either within the Emergency Department or within 72 h as
an outpatient (as recommended by the AHCPR). The
observation of the low yield of low risk patients by the
AHCPR model concurs with study of Katz et al. (10) who
found that the AHCPR model identified only 6% of
patients. Third, the risk gradient for MI, death or heart
failure between medium and high-risk patients was small for
both models making the distinction between medium and
high risk of this composite end point of less clinical value.
However, the RUSH model did demonstrate an ability to
discriminate a composite end point of death, MI, heart
failure or recurrent angina with ST depression compared to
the AHCPR model. The inclusion of ST depression with
recurrent angina makes this secondary end point reasonably
objective and clinically meaningful. The RUSH model also
better discriminates recurrent angina which is arguably a
soft end point. Indeed, the AHCPR guidelines are weighted
more toward complicating heart failure, which was a rare
complication in this study and may have influenced the
performance of that model.
Admittedly, some bias may exist for nurse data collectors
to underestimate complications in low risk patients by virtue
of early hospital discharge and incomplete follow-up. This
risk appears to be small by virtue of similar hospital length
of stay among risk groups of either model. Patients dis-
charged from the Emergency Department because they
were low risk may also have affected these results since they
were not included in the analysis. Our experience with these
patients, which has been recently reported, suggests lower
event rate than reported in the low risk categories of this
study (21).
Potential impact of changes in concurrent therapy. Ag-
gressive medical therapy directed by clinical practice guide-













*AHCPR 5 Agency for Health Care Policy and Research.
Table 3. Results: Comparison of Therapy by Groups*
RUSH AHCPR
Low Medium High p Value Low Medium High p Value
IV Nitroglycerin, n (%) 29 (28) 134 (53) 45 (76) 0.001 8 (36) 135 (48) 66 (58) 0.072
IV Heparin, n (%) 78 (74) 208 (83) 49 (83) 0.154 20 (91) 218 (78) 98 (87) 0.053
Surgery, n (%) 8 (8) 31 (12) 10 (17) 0.188 2 (9) 37 (13) 10 (9) 0.448
PTCA, n (%) 27 (26) 60 (24) 17 (29) 0.724 3 (14) 69 (25) 32 (28) 0.331
Beta-blocker, n (%) 55 (52) 129 (51) 29 (49) 0.924 12 (55) 145 (52) 56 (56) 0.888
AHCPR 5 Agency for Health Care Policy and Research; PTCA 5 percutaneous transluminal coronary angioplasty.
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lines was promoted by the design of this study and may have
reduced ischemic complications, especially in higher risk
groups of both models. This may also have obscured the
distinction between medium and high risk patients, by
lowering the complication rate in the high risk categories as
we have previously demonstrated (22).
The RUSH model appears to demonstrate a trend toward
predicting the use of coronary bypass surgery and medical
therapy such as IV heparin. Neither model predicted the use
of coronary angioplasty. This latter finding was also appar-
ent in an earlier study by our group (23) and by others
(24,25), leading one editorialist to suggest another model to
assess the need for angioplasty in patients with unstable
angina (26). This is disconcerting in light of the recently
reported results of the VANQWISH (27) and MATE (28)
trials and the OASIS Registry (23,29) of acute ischemic
syndromes, which have not demonstrated dramatic benefit
from early angioplasty and may have demonstrated potential
harm. Further studies with IIb/IIIa platelet receptor inhib-
itors and early coronary intervention are necessary to answer
this question.
Novel methods of risk stratification. Neither risk predic-
tion model studied includes laboratory markers for risk such as
troponin I or T, early stress testing or multi-lead ST segment
monitoring. Troponin was not available in our institution at
the time of the study. Several authors (30–35) have suggested
the potential value of either troponin I or T to predict risk of
complication in acute ischemic syndromes. In fact, a recent
study by Hamm et al. (6) suggests an excellent prognosis if
either of these markers is negative. However, none of these
studies was designed to demonstrate any incremental value of
a troponin marker over clinical predictors. Therefore, the
National Heart Attack Alert Program (36) still suggests further
evaluation from carefully controlled studies. Because the low
risk groups studied herein had very low event rates, a prospec-
tive head-to-head comparison of troponin is necessary in this
risk group. It is possible that these markers may have greater
value in refining the risk estimates in intermediate and high
risk groups.
Some clinicians may be uncomfortable with defining “low
risk” groups in unstable angina using event rates of 2% to
5%. While Selker and colleagues (13) have demonstrated an
extremely low mortality rate in low risk chest pain patients
identified by a multivariate predictive instrument, only 25%
of patients had an acute ischemic syndrome. Currently, we
are testing the effectiveness of combining clinical prediction
models with early stress echocardiography. The RUSH
model appears to be attractive for this purpose because it
predicts a larger proportion of patients who appear to be
clinically at low risk. Current AHCPR guidelines recom-
mend outpatient noninvasive testing within 48 h for this
group. While rest echocardiography (37), rest sestamibi
(38), stress nuclear testing (39) and stress echocardiography
(40–42) have been used to assess risk of chest pain patients
in the Emergency Department, pretest probabilities are
seldom reported. The RUSH model provides an objective
pretest probability, thereby enhancing patient selection for
early noninvasive testing (12 to 18 h) and improving
posttest estimates or risk.
In this study, patients identified by the RUSH model to
be at high risk for major cardiac complications had a
complication rate for MI, death or heart failure that was
lower than predicted by the model. More aggressive therapy
may have been responsible, although explanations such as
unidentified changes in comorbidity may also be responsi-
ble. This finding highlights the need to interpret our
findings in the light of current treatment practices and
patient selection. Potentially, the use of new serum markers
or multi-lead ST segment monitoring could further refine
our predictions of high risk patients.
In summary, this study confirms the value of clinical
risk prediction to identify the low, medium and high risk
patients with unstable angina. It not only validates the
use of the AHCPR model for distinguishing low risk
from medium and high risk patients but also shows that
another easily applied model may identify more low risk
patients and better predicts a composite of ischemic com-
plications. These risk prediction models may have a poten-
tial impact on the use of glycoprotein IIb/IIIa platelet
receptor inhibitors and enoxaparin and earlier use of PTCA
and stents.














(n 5 59) p Value
Heart failure, n (%) 0 (0) 7 (3) 4 (4) 0.738 0 (0) 9 (4) 2 (3) 0.147
MI, n (%) 1 (5) 9 (3) 2 (2) 0.664 1 (1) 7 (3) 4 (7) 0.101
Death, n (%) 0 (0) 3 (1) 3 (3) 0.539 2 (2) 3 (1) 0 (0) 0.562
MI or death, n (%) 1 (5) 12 (5) 4 (4) 1.00 3 (3) 10 (4) 4 (7) 0.472
Heart failure, MI or death, n (%) 1 (5) 19 (7) 9 (8) 0.887 3 (3) 19 (8) 6 (10) 0.128
Recurrent angina, n (%) 2 (9) 37 (13) 16 (14) 0.876 10 (10) 31 (12) 14 (24) 0.029
Recurrent angina with ST depression, n (%) 0 (0) 7 (3) 3 (3) 1.00 1 (1) 4 (2) 5 (9) 0.004
Heart failure, MI, death or recurrent angina
with ST depression, n (%)
1 (5) 26 (9) 12 (11) 0.665 4 (4) 23 (9) 11 (19) 0.007
Any 3 (14) 56 (20) 25 (22) 0.650 13 (12) 50 (20) 20 (34) 0.004
*MI 5 myocardial infarction.
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